Table 1 Characteristics of the studies included in the meta-analysis
Author | Year | Country | Study date | Sample size | Cut-off value | Prognosis | Patients included | Follow-up (month) | NOS score | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
High ALI | Low ALI | Total | |||||||||
Horino T [21] | 2021 | Japan | 2005–2019 | 532 | 281 | 813 | NA | OS、RFS | CRC | NA | 9 |
Pian G [22] | 2020 | Korea | 2009–2018 | 32 | 100 | 132 | 70.4 | OS、DFS | CRC patients with liver metastases | NA | 6 |
Kusunoki K [23] | 2020 | Japan | 2005–2011 | 224 | 74 | 298 | NA | OS、DFS | CRC | 36.8 (39.7 ± 29.0)a | 8 |
Xie HL [24] | 2020 | China | 2012–2014 | 423 | 239 | 662 | manle31.6; female24.4 | OS、PFS | CRC | 63 (1–80)b | 9 |
Shinutani M [25] | 2019 | Japan | 2008–2016 | 92 | 67 | 159 | 28.9 | OS | unresectable metastatic CRC patients underwent combination chemotherapy | 21.6 (1.2–94.0)b | 6 |
Chen C [26] | 2022 | China | 2012–2016 | 130 | 179 | 309 | 25.71 | OS | CRC | 60 (1–98)b | 8 |
Yin CZ [28] | 2021 | Japan | 1992–2011 | NA | NA | 620 | 30.0 | OS、DFS | GC | 52.8 ± 39.9c | 9 |
Zhang X [29] | 2022 | China | 2010–2017 | 362 | 253 | 615 | 39.77 | OS、DFS | GC | 40 (25–64)b | 9 |
Deng Y [27] | 2022 | China | 2012–2016 | 205 | 236 | 441 | 36.3 | OS、DFS | right-sided colon cancer | 65 (3–110)b | 8 |
Tan X [30] | 2021 | China | 2013–2018 | 57 | 101 | 158 | 31.24 | OS | EC | 29–88d | 7 |
Feng JF [31] | 2014 | China | 2006–2008 | 173 | 120 | 293 | 18.0 | CSS | EC | 35–71d | 8 |
Li Q [32] | 2022 | China | 2017–2020 | 35 | 30 | 65 | 34.7 | OS | advanced HCC | at least 24 months | 7 |
Wu H [33] | 2022 | China | 2016–2019 | 35 | 62 | 97 | 31.8 | OS、DFS | cholangiocarcinoma | 20 (3–70)b | 7 |
Barth DA [34] | 2020 | Austria | 2003–2015 | NA | NA | 429 | 43.5 | CSS | PC | NA | 9 |